Replies to post #81892 on Anavex Life Sciences Corp (AVXL)

[Amatuer17]

I know it is not worthwhile spending time on debating this point as the presentation will make things clear in one week.

Here is key point - look at the 31 week poster presented - it clearly shows graph of data with D and w/o D

This means at least till week 31 - the patients (n=25 or 23) were taking D - there is no mention of these patients stopping D even though poster clearly mentions that with ot without D the results did not differ.

Also if you go to clinicaltrials site and look at history of changes - it mentions changes to protocol - such change is not mentioned for stopping usage of D

So my conclusion is - n=25 probably continued with D as stopping them may not be as easy. As such I expect the data to be for both sets of patients not only with monotherapy.

Dr Mac may try to convince them to stop D for the 2nd extension of 104 week